已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Clinical study of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma

医学 多西紫杉醇 卡铂 养生 内科学 新辅助治疗 肿瘤科 外科 化疗 存活率 完全响应 不利影响 胃肠病学 癌症 顺铂 乳腺癌
作者
Guoliang Zhang,Qi-Kun Zhu,Tianyou Ma,Chen-Gang Weng,Dandan Zhang,Hui Zeng,Tao Wang,Feng Gao,Li-Li Mi,Rui Wang
出处
期刊:Diseases of The Esophagus [Oxford University Press]
卷期号:37 (4)
标识
DOI:10.1093/dote/doad073
摘要

Summary Herein, we aimed to evaluate the efficacy and safety of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma (OSCC). Fifty-one patients with OSCC, treated from July 2020 to October 2022, were analyzed. Of them, 41 patients underwent surgery 4–8 weeks after undergoing two cycles of camrelizumab (200 mg IV Q3W) combined with docetaxel (75 mg/m2 IV Q3W) and carboplatin (area under the curve = 5–6 IV Q3W). The primary endpoint was the pathological complete response rate. All 51 patients (100%) experienced treatment-related grades 1–2 adverse events, and 2 patients (3.9%) experienced grade 4 events (including elevated alanine transaminase/aspartate transferase levels and Guillain–Barre syndrome). Fifty patients were evaluated for the treatment efficacy. Of them, 13 achieved complete response, and the objective response rate was 74%. Only 41 patients underwent surgical treatment. The pathological complete response rate was 17.1%, the major pathological response rate was 63.4%, and the R0 resection rate was 100%. Approximately 22% of the patients had tumor regression grades 0. Eight patients (19.5%) developed surgery-related complications. The median follow-up time was 18 months (range: 3–29 months). Four patients experienced disease progression, while four died. The median disease-free survival and overall survival were not reached. Camrelizumab combined with docetaxel and carboplatin is an effective and safe neoadjuvant treatment for locally advanced OSCC. This regimen may afford a potential strategy to treat patients with locally advanced OSCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
xzgwbh应助程瑞哲采纳,获得10
3秒前
寻雾启事完成签到,获得积分10
5秒前
韩凡发布了新的文献求助10
13秒前
hua完成签到,获得积分10
15秒前
琉璃发布了新的文献求助10
15秒前
15秒前
orixero应助机智的善愁采纳,获得10
16秒前
Garnieta发布了新的文献求助10
16秒前
耀阳完成签到 ,获得积分10
18秒前
19秒前
潇洒的小鸽子完成签到 ,获得积分10
19秒前
可靠板栗发布了新的文献求助10
19秒前
Garnieta完成签到,获得积分10
27秒前
香蕉觅云应助清宁亦无拘采纳,获得10
28秒前
量子星尘发布了新的文献求助10
29秒前
可靠板栗完成签到,获得积分10
30秒前
王旭鸣完成签到,获得积分10
34秒前
Ava应助司空豁采纳,获得10
36秒前
37秒前
阿司匹林发布了新的文献求助10
43秒前
46秒前
李健应助阿司匹林采纳,获得10
47秒前
49秒前
49秒前
51秒前
51秒前
核桃应助科研通管家采纳,获得10
52秒前
烟花应助科研通管家采纳,获得10
52秒前
52秒前
张海洋应助溯桀采纳,获得10
52秒前
猪猪hero应助科研通管家采纳,获得10
52秒前
52秒前
52秒前
猪猪hero应助科研通管家采纳,获得10
52秒前
yznfly应助科研通管家采纳,获得20
52秒前
顾矜应助小瓶子采纳,获得10
52秒前
52秒前
阿司匹林完成签到,获得积分10
54秒前
Hermie发布了新的文献求助10
54秒前
高分求助中
The Oxford Encyclopedia of the History of Modern Psychology 2000
Chinesen in Europa – Europäer in China: Journalisten, Spione, Studenten 1200
Deutsche in China 1920-1950 1200
Applied Survey Data Analysis (第三版, 2025) 850
Mineral Deposits of Africa (1907-2023): Foundation for Future Exploration 800
 Introduction to Comparative Public Administration Administrative Systems and Reforms in Europe, Third Edition 3rd edition 590
Learning to Listen, Listening to Learn 570
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3881354
求助须知:如何正确求助?哪些是违规求助? 3423741
关于积分的说明 10735897
捐赠科研通 3148676
什么是DOI,文献DOI怎么找? 1737344
邀请新用户注册赠送积分活动 838802
科研通“疑难数据库(出版商)”最低求助积分说明 784087